1,711,831 Shares in Haleon plc (NYSE:HLN) Acquired by UBS Group AG

Posted by on Feb 24th, 2023

UBS Group AG purchased a new position in Haleon plc (NYSE:HLN – Get Rating) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,711,831 shares of the company’s stock, valued at approximately $10,425,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Whittier Trust Co. of Nevada Inc. bought a new position in shares of Haleon in the third quarter valued at approximately $28,000. Assetmark Inc. purchased a new stake in Haleon in the third quarter worth $29,000. Hudock Inc. purchased a new stake in Haleon in the third quarter worth $30,000. Benjamin F. Edwards & Company Inc. purchased a new stake in Haleon in the third quarter worth $33,000. Finally, City Holding Co. purchased a new stake in Haleon in the third quarter worth $34,000. Institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

HLN has been the subject of a number of recent research reports. Barclays raised their target price on Haleon from GBX 360 ($4.34) to GBX 364 ($4.38) in a research report on Tuesday, January 31st. Investec assumed coverage on Haleon in a research report on Thursday. They set a “sell” rating on the stock. Finally, Morgan Stanley raised shares of Haleon from an “equal weight” rating to an “overweight” rating in a report on Friday, January 6th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $364.00.

Haleon Price Performance

Shares of Haleon stock opened at $8.08 on Friday. The company’s 50-day moving average price is $7.97 and its 200-day moving average price is $6.95. Haleon plc has a 12-month low of $5.59 and a 12-month high of $8.50.

Haleon Profile

(Get Rating)

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.

Read More

Institutional Ownership by Quarter for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.